The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Microbial Immunology
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1537520
This article is part of the Research Topic Lung Adenocarcinoma: From Genomics to Immunotherapy, Volume II View all 6 articles
Mycobacterium tuberculosis infection may increase the degrees of malignancy in lung adenocarcinoma
Provisionally accepted- Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
The early diagnosis and management of lung adenocarcinoma coexisting with tuberculosis (LAC-TB) presents significant challenges in clinical settings. This is compounded by a paucity of robust clinical evidence elucidating the interactions between these two conditions.Methods: This study included 14 patients diagnosed with LAC-TB, with an equal distribution among those with pulmonary tuberculosis (TB) and those with peripheral lymph node TB. Controls included patients with simple TB and those with lung adenocarcinoma (LAC). Histopathologic examinations confirmed typical changes in each group. Immunohistochemistry analyzed immune markers, focusing on PD-L1, while genomic analysis identified differential mutant genes.Results: Pathological evaluations showed that LAC-TB and LAC groups expressed TTF-1 and Napsin A in their adenocarcinoma specimens. Notably, a higher proportion of patients in the LAC-TB group had a Ki-67 proliferation index of ≥10%. Subsequent Molecular analyses revealed significant differences in RALGAPA1 gene expression, with the LAC-TB group also exhibiting a greater median count of missense mutations, single nucleotide polymorphisms, and overall mutations, suggesting a higher malignancy level than the LAC group. Additionally, the LAC-TB group showed an increased tumor mutational burden, indicating a potentially better response to immunotherapy. Immunohistochemical assessments indicated that Mycobacterium tuberculosis (MTB) infection correlated with reduced infiltration of T cells and CD4 + T cells, alongside an upregulation of PD-L1 expression in LAC. Notably, PD-L1 was strongly expressed in the TB granuloma and surrounding areas.Our findings suggest that MTB infection may increase the malignancy of LAC, with the pronounced expression of PD-L1 in granuloma regions constituting a pivotal mechanism underlying this relationship.
Keywords: Mycobacterium tuberculosis, lung cancer, Immunotherapy, PD-L1, Granuloma
Received: 01 Dec 2024; Accepted: 04 Feb 2025.
Copyright: © 2025 Li, Feng, Wang, Liu, Li, Dai, Yang, Chai and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mengru Feng, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Fenghua Wang, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Dongxu Liu, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Mingyan Li, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Jinlong Dai, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Yan Yang, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Yinghui Chai, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Wen Chen, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.